A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Inclusion Criteria

• •1. Diagnosis of CD19-positive relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).
• •2. Must have met the following criteria for prior treatment:
• •1. Participants with aggressive NHL must have received at least 2 lines of systemic therapy (if not intended for transplant, have already undergone or be unwilling or unable to undergo chimeric antigen receptor \[CAR\] T-cell therapy to be eligible), or at least 3 lines of systemic therapy. Previous therapy must have included a CD20-targeted agent and an anthracycline or alkylator.
• •2. Participants with follicular lymphoma (FL) must have received at least 2 lines of systemic therapy and have high-risk disease. Previous therapy must have included a CD20-targeted agent and an alkylator.
• •3. Participants with marginal zone lymphoma (MZL) must have received at least 2 prior systemic therapies.
• •3. Measurable disease on screening evaluations.
• •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• •5. Adequate organ function.
• •6. Life expectancy of ≥12 weeks.